A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Amicus Therapeutics Inc (NASDAQ:FOLD) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on January 1, 2018 and NASDAQ:FOLD investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/27/2017 -- The Shareholders Foundation announces that a deadline is coming up on January 1, 2018 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Amicus Therapeutics Inc (NASDAQ:FOLD) between March 19, 2015 and October 1, 2015.
Investors who purchased a significant amount of shares of Amicus Therapeutics Inc (NASDAQ:FOLD) between March 19, 2015 and October 1, 2015, have certain options and should contact the Shareholders Foundation by email at email@example.com or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Amicus Therapeutics Inc (NASDAQ:FOLD) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/amicus-therapeutics-inc-nasdaq-fold-investor-securities-class-action-lawsuit-10072015
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is January 1, 2018. The class action administrator for this case is Amicus Securities Litigation.
The lawsuit was originally filed in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Amicus Therapeutics Inc in connection with certain allegedly false and misleading statements made between March 19, 2015 and October 1, 2015. According to the complaint the plaintiff alleges on behalf of purchasers of Amicus Therapeutics Inc (NASDAQ:FOLD) common shares between March 19, 2015 and October 1, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 19, 2015 and October 1, 2015 defendants issued a series of allegedly false and misleading statements that misrepresented that Amicus Therapeutics Inc had an "approval pathway" for its lead product candidate Galafold, by which it would submit a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for "accelerated approval" of the drug "in the second half of 2015 and that defendants represented that Amicus Therapeutics Inc's two Phase III global registration studies of Galafold "have shown that treatment with migalastat has resulted in reductions in disorder substrate, stability of kidney function, reductions in cardiac mass, and improvement in gastrointestinal symptoms."
The plaintiff claims that defendants allegedly failed to disclose, among other things, that Amicus Therapeutics Inc's two Phase III studies failed to satisfy the FDA's concerns over migalastat's effect on gastrointestinal symptoms; that the FDA required full integration and additional analyses of clinical data from the Phase III studies, and that as a result, Amicus Therapeutics Inc had no reasonable basis to represent that it would submit its NDA for accelerated approval in the second half of 2015.
Those who purchased shares of Amicus Therapeutics Inc (NASDAQ:FOLD) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego